Review
The Research Progress of Nanoimmunotherapy to Treat Ischemic Heart Disease
Yao Liu 1,2,*,✉, Jun-Li Jin 3,*
1Department of Clinical Medicine, The First Clinical Medical College, Yangtze University, Jingzhou, Hubei 434023, China; 2School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, Hubei 434023, China; 3Department of cardiovascular medicine, The First people Hospital, Jingzhou, Hubei 434023 , China;.
* These authors contributed equally. ✉ Correspondence Yao Liu, Department of Clinical Medicine, the First Clinical Medical College, Yangtze University, Jingzhou, Hubei 434023, China. Email: [email protected]. Telephone number: 18971124806. Received: May 2, 2020; Accepted: September 3, 2020; Published online: October 15, 2020. Cite this paper: Yao Liu, Jun-Li Jin. (2020) The research progress of nanoimmunotherapy to treat ischemic heart disease. Global Journal of Immunology, 1(1):9-16. https://naturescholars.com/gji.010103. https://doi.org/10.46633/gji.010103. Copyright © 2020 by Scholars Publishing, LLC.
Abstract
The mortality of cardiovascular diseases (CVDs) is gradually increasing, and atherosclerosis is the main potential cause of myocardial infarction and stroke. Atherosclerosis is resulted from cholesterol accumulation and later inflammation in the vessel wall. Although lipid-lowering therapy is still the cornerstone of atherosclerosis disease management at present, researchers have paid attention to inflammatory factors in atherosclerotic diseases as therapeutic targets. In 2017, the CANTOS trial demonstrated for the first time that the targeted IL-1β antibody canakinumab can reduce the major cardiovascular adverse events (MACE) of patients after myocardial infarction by 15%, which proved the beneficial effect of targeted anti-inflammation therapy in treating cardiovascular diseases for the first time. At the same time, animal model tests mediated by nano-immunotherapy have proved that nano-immunotherapy could reduce inflammation and prevent the progression of plaque, thus supporting the transformability of the method and the potential for the treatment of atherosclerosis.
Key words: Atherosclerosis, Ischemic Heart Disease Nano-Immunotherapy, CD40-Tumor Necrosis Factor Receptor-Related Factor 6 (TRAF6).